deamidation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reconstitution is a critical handling step. The appropriate solvent—often sterile water, phosphate-buffered saline, or a water-acetonitrile mixture—is chosen based on peptide solubility. Adding solvent gently down the vial wall and swirling, rather than vortexing, reduces foaming and shear stress. The resulting solution should be clear; visible particles indicate incomplete dissolution or contamination. Concentration is recorded accurately because it affects subsequent use. If the peptide is not fully soluble, a small amount of organic solvent or a different buffer may be required, but this changes the final composition.
After reconstitution, solutions are divided into single-use aliquots and stored at -80°C. Labels include peptide name, concentration, buffer composition, date, and lot number. Freeze-thaw cycles are minimized by thawing only the needed aliquot on ice or at room temperature. Some peptides benefit from the addition of a carrier protein, such as bovine serum albumin, or a cryoprotectant like glycerol to reduce adsorption to plastic. Glass vials with low-binding surfaces are preferred for dilute solutions. Shipping of frozen aliquots uses dry ice and insulated containers to maintain the cold chain.
Receiving a peptide shipment requires immediate inspection of the packaging and temperature indicators. Any deviation from the specified cold chain should be documented and investigated. Upon arrival, solid peptides are generally kept at -20°C, whereas liquid formulations are stored at -80°C. Vials should be kept upright and protected from light. Repeated warming and cooling of the entire container is avoided by preparing smaller working aliquots. A log of lot numbers, receipt dates, and storage locations supports traceability and quality control.
Peptides are short chains of amino acids whose physical and chemical stability depends on sequence, length, conformation, and the surrounding matrix. In the solid state, lyophilized powders are generally more stable than solutions because low water activity slows hydrolysis and oxidation. Residual moisture, oxygen, trace metals, and light can still promote degradation over time. Storage recommendations therefore balance temperature, humidity, and container integrity rather than relying on a single condition. The optimal condition for a given peptide is often determined empirically because no universal rule covers every sequence.
In aqueous solution, peptides are vulnerable to hydrolysis, oxidation, deamidation, and aggregation, with rates influenced by pH, temperature, buffer composition, and ionic strength. Acidic or neutral pH ranges often slow deamidation, while extreme pH can accelerate peptide bond cleavage. Dissolved oxygen and redox-active metal ions contribute to oxidation of methionine, cysteine, and tryptophan residues. Aggregation may be driven by hydrophobic interactions or by interfaces such as air-liquid and container surfaces. Because these pathways interact, solution storage usually requires tighter control than storage of dried material.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (lyophilized) | -20°C | Stable for months to years; avoid frost-free freezers |
| Storage temperature (solution) | -80°C | Single-use aliquots preferred; avoid repeated freeze-thaw |
| Reconstitution solvent | Sterile water or buffer | Choice depends on peptide solubility and application |
| Container material | Glass or polypropylene | Low protein-binding surfaces reduce adsorption |
| Shipping condition | Dry ice | Insulated packaging maintains cold chain during transit |
Reconstitution solvent depends on peptide solubility and intended use; water, buffer, or small amounts of organic solvent may be needed. After dissolution, solutions are typically aliquoted into single-use portions to avoid repeated freeze-thaw cycles. Aliquots are stored at -20 °C or -80 °C, depending on stability. Labels include concentration, solvent, date, and operator. Sterile filtration may be used when microbial control is required, but filters can adsorb peptides. The optimal concentration and solvent are often determined empirically.
Cold-chain shipping uses insulated containers, phase-change packs, and temperature indicators. Dry ice maintains -70 °C or lower but requires venting to avoid pressure buildup. Gel packs provide 2-8 °C for shorter transit. Upon arrival, recipients should record temperature indicators and transfer vials promptly to storage. Deviations from specified conditions should be documented and may require analytical re-check. The effect of a brief temperature excursion is peptide-specific and not always predictable from general rules.
Handling begins with receipt and inspection. Vials should be checked for damage, label integrity, and temperature history. Lyophilized peptides should be allowed to equilibrate to room temperature before opening to prevent condensation. Solutions should be prepared in a clean, calibrated environment using appropriate solvents. Personal protective equipment and containment reduce exposure and contamination. Documentation of lot number, date, and storage location supports traceability. The goal is to limit repeated temperature changes, moisture exposure, and microbial contamination.
Moisture, oxygen, and light also affect peptide integrity. Lyophilized powders absorb water from the air, which can enable hydrolysis and conformational changes. Oxygen promotes oxidation of sensitive residues, so storage under inert gas or in sealed vials is common. Light exposure can cause photodegradation, particularly for peptides containing aromatic amino acids. Buffer choice and pH influence charge state and solubility; extremes of pH accelerate deamidation and hydrolysis. Adding stabilizers such as sugars or polyols can protect the peptide during freezing and drying. Optimal conditions are determined empirically for each peptide.
Peptides are short chains of amino acids that can undergo both chemical and physical degradation. Chemical pathways include hydrolysis of peptide bonds, oxidation of methionine or cysteine residues, deamidation of asparagine or glutamine, and isomerization of aspartate. Physical instability leads to aggregation, precipitation, or adsorption to surfaces. The rate of these processes depends on the peptide sequence, the formulation, and the storage environment. Because each peptide has a unique composition, no single storage condition applies to all peptides. Stability studies are therefore conducted to define suitable conditions for each specific molecule.
Temperature is a primary factor in peptide storage. Lower temperatures reduce molecular motion and slow degradation reactions, but freezing can concentrate solutes and promote aggregation. Lyophilized powders are commonly held at -20°C, whereas solutions are often kept at -80°C. Repeated freeze-thaw cycles are harmful because ice crystal formation and pH shifts can damage the peptide. The glass transition temperature of a lyophilized cake influences its stability; below this temperature, molecular mobility is restricted. For solutions, the choice between -20°C and -80°C depends on the peptide's sensitivity and the intended storage duration.
After reconstitution, solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. Aliquots should be labeled with peptide identity, concentration, solvent, and date, then stored at the temperature specified by the supplier or protocol. Many peptides tolerate -20 °C for short periods, while -80 °C is preferred for longer storage. Frost-free freezers are generally avoided because temperature fluctuations can stress samples. Aseptic technique and sterile filters reduce microbial contamination, though filtration can also remove aggregated material or bind some peptides.
Peptide handling begins with careful receipt and inventory. Containers should be inspected for damage, label information should match the certificate of analysis, and storage location should be recorded. Many lyophilized peptides are electrostatic and may cling to vial walls or weighing paper, which can complicate transfer. Allowing a cold vial to equilibrate to room temperature before opening reduces condensation on the contents. Clean tools, gloves, and a low-humidity workspace limit contamination and moisture exposure during manipulation.
Aseptic technique reduces microbial and particulate contamination when a peptide solution will be used in cell culture or other sensitive applications. Work in a clean area, use sterile containers and filtered tips, and avoid touching vial interiors. Preparing aliquots immediately after dissolution limits repeated temperature cycling, which is a common cause of aggregation and activity loss. Low-binding plastic tubes are preferred for peptides that adsorb to surfaces, especially hydrophobic or positively charged sequences. Labels should record identity, solvent, concentration, and preparation date so that later use can be traced.
Shipping and short-term transfer require attention to temperature control and physical stability. Frozen solutions are commonly sent on dry ice, while lyophilized powders may travel with gel packs or insulated packaging. Thawing should be done slowly on ice or in a refrigerator, not by vigorous heating, and the solution should be mixed gently before use. Temperature loggers can document excursions during transit, but their presence does not prove that a peptide remained stable. Analytical checks such as chromatography or mass spectrometry can verify identity and purity after storage or shipping.
Reconstitution begins with selecting a solvent that dissolves the peptide without causing degradation. Water or aqueous buffer is suitable for many hydrophilic sequences, while hydrophobic peptides may require a small amount of organic solvent such as acetonitrile or dimethyl sulfoxide before dilution. The solvent is added to the vial rather than the powder being scraped out, and the mixture is swirled or inverted gently to avoid foaming. Complete dissolution should be confirmed visually, and insoluble material may indicate aggregation or impurities. Because solvent tolerance varies, published solubility information or a small test dissolution can guide handling.
"Biosafety in Microbiological and Biomedical Laboratories", official CDC guide. "Prevention of Biological Hazards", EU-OSHA "Symbol Making", an account of the development of the symbol in 1966. "BioSeal Systems", Biosafety level 4 containment. Biohazard Remediation Compliance Overview "Example of Reclassified Biohazard to Level 4", article from The Lancet concerning the reclassification of Ebola after observation. "Biological hazards related to working alone safety", an article focusing on working alone safety when dealing with biological hazards
The source of ADP-ribose for most enzymes that perform this modification is the redox cofactor NAD+. In this transfer reaction, the N-glycosidic bond of NAD+ that bridges the ADP-ribose molecule and the nicotinamide group is cleaved, followed by nucleophilic attack by the target amino acid side chain. (ADP-ribosyl)transferases can perform two types of modifications: mono(ADP-ribosyl)ation and poly(ADP-ribosyl)ation.
Kunitz-type serine protease inhibitor APEKTx1 is a peptide toxin derived from the sea anemone Anthopleura elegantissima. This toxin has a dual function, acting both as a serine protease inhibitor and as a selective and potent pore blocker of Kv1.1, a shaker related voltage-gated potassium channel. APEKTx1 is a potent toxin purified from the sea anemone A. elegantissima. Besides APEKTx1, other toxins such as APETx1, APE1-1, APE1-2, APE2-2, ApC, and APETx2 have been identified in A. elegantissima. This peptide has 65 amino acids crosslinked by 3 disulphide bridges, and has a molecular mass of 7475 Da. It acts as a monomer. The toxin belongs to the type 2 sea anemone peptides targeting voltage-gated K channels. Other type 2 toxins are the kalicludines from Anemonia sulcata, which selectively block Kv1.2 channels, and SHTX II from Stichodactyla haddoni. Structural homology is also shared with the basic pancreatic trypsin inhibitor (BPTI), a very potent Kunitz-type protease inhibitor, and dendrotoxins (DTX I and α-DTX), which are potent inhibitors of voltage-gated potassium channels.
Sources: en.wikipedia.org
The main building of the Institute is located at the intersection of Kremlyovskaya and Lobachevskaya streets. This four-story building built in 1953 in the style of Soviet neoclassicism under the guidance of architect A.G. Bikchentaev. The building of the museum of Kazan chemical school is located in the campus of the main university building, built in the 1830s in a classical style under the guidance of architect M.P. Corinfskiy. In 2015 construction of a large laboratory building in the campus of Alexander Butlerov Institute of Chemistry was finished. The 7-storey building housed classrooms and laboratories of departments of Alexander Butlerov Institute of Chemistry, Institute of Geology and Petroleum Technologies, Institute of Physics. The building was constructed with the support of the President of Tatarstan R.N. Minnikhanov and PSC "TAIF".
This enzyme is the extracellular nuclease of Staphylococcus aureus. Two strains, V8 and Foggi, yield almost identical enzymes. A common source is E.coli cells carrying a cloned nuc gene encoding Staphylococcus aureus extracellular nuclease (micrococcal nuclease). The 3-dimensional structure of micrococcal nuclease (then called Staphyloccal nuclease) was solved very early in the history of protein crystallography, in 1969. Higher-resolution, more recent crystal structures are available for the apo form and for the thymidine-diphosphate-inhibited form. As seen in the ribbon diagram above, the nuclease molecule has 3 long alpha helices and a 5-stranded, barrel-shaped beta sheet, in an arrangement known as the OB-fold (for oligonucleotide-binding fold) as classified in the SCOP database.
Eq. 3 This means that coconut oil with an abundance of medium chain fatty acids (mainly lauric acid) contain more fatty acids per unit of weight than, for example, olive oil (mainly oleic acid). Consequently, more ester saponifiable functions were present per g of coconut oil, which means more KOH is required to saponify the same amount of matter, and thus a higher SV. The calculated molecular weight (Eq. 3) is not applicable to fats and oils containing high amounts of unsaponifiable material, free fatty acids (> 0.1%), or mono- and diacylglycerols (> 0.1%).
Dysphoria and apathy (due to dopamine receptor blockade) Sedation (particularly common with asenapine, clozapine, olanzapine, quetiapine, chlorpromazine and zotepine) Headaches Dizziness Diarrhea Anxiety Extrapyramidal side effects (particularly common with first-generation antipsychotics), which include: Akathisia, an often distressing sense of inner restlessness. Dystonia, an abnormal muscle contraction Pseudoparkinsonism, symptoms that are similar to what people with Parkinson's disease experience, including tremulousness and drooling Hyperprolactinaemia (rare for those treated with clozapine, quetiapine and aripiprazole), which can cause: Galactorrhoea, the unusual secretion of breast milk. Gynaecomastia, abnormal growth of breast tissue Sexual dysfunction (in both sexes) Osteoporosis Orthostatic hypotension Weight gain (particularly prominent with clozapine, olanzapine, quetiapine and zotepine, can be counteracted by starting the drug with metformin) Antipsychotic medication-induced weight gain (AIWG) is a difficult-to-manage condition. In a meta-analysis analyzing data from 9 studies having more than 40,000 patients with AIWG, use of semaglutide was on an average was associated with 7.37kg weight loss with a good reduction in waist circumference. The occurrence of psychiatric adverse events was lower in semaglutide users.
Sources: en.wikipedia.org
June 29 – July 6: 2019 Men's U20 European Lacrosse Championship in Prague (debut event) England defeated Germany, 9–8, to win the inaugural Men's U20 European Lacrosse Championship title. The Czech Republic took third place. July 16 – 25: 2019 Women's European Lacrosse Championship in Netanya England defeated Israel, 10–7, to win their third consecutive and seventh overall Women's European Lacrosse Championship title. Wales took third place. August 1 – 10: 2019 FIL Women's Under-19 World Lacrosse Championships in Peterborough The United States defeated Canada, 13–3, to win their fifth Women's Under-19 World Lacrosse Championships title. Australia took third place. September 19 – 28: 2019 World Indoor Lacrosse Championship in Langley Canada defeated Haudenosaunee, 19–12, to win their fifth consecutive World Indoor Lacrosse Championship title. United States took third place.
Ansuvimab was developed by the Vaccine Research Center with support of the United States National Institutes of Health and the Defense Advanced Projects Agency. The heavy and light chain sequences of ansuvimab mAb were cloned into CHO cell lines to enable large-scale production of antibody product for use in humans. In early 2018, a Phase 1 clinical trial of ansuvimab's safety, tolerability and pharmacokinetics was conducted by Dr. Martin Gaudinski within the Vaccine Research Center Clinical Trials Program that is led by Dr. Julie E. Ledgerwood. The study was performed in the United States at the NIH Clinical Center and tested single dose infusions of ansuvimab infused over 30 minutes. The study showed that ansuvimab was safe, had minimal side effects and had a half-life of 24 days. A license for ansuvimab was obtained by Ridgeback Biotherapeutics in 2018, from the National Institutes of Health-National Institute of Allergy and Infectious Diseases. Ansuvimab was given orphan drug status in May 2019 and March 2020.
The heavily phosphorylated β-sheet of caddisfly larvae contains strong negative charges which have been found to interact with di- and trivalent cations found naturally within the larvae's aquatic environment. These cations, including calcium, magnesium, and iron, are vital to maintaining the rigid structure of the silk's β-sheet. The ionic interactions between negatively charged serines and these cations produce a crystal with a unit cell of 5.9 Angstroms x 23.3 Angstroms x 17.3 Angstroms, as determined by X-Ray diffraction. The necessity of these cations was shown using EDTA to chelate and remove them from the protein structure, producing a mobile, noncrystalline protein. Reintroduction of monovalent ions failed to restore the crystalline structure, however reintroduction of calcium or other multivalent ions successfully restored the rigidity to the H-fibroin protein.
Bio-Synthesis, Inc. (BSI) is a biotechnology company headquartered in Lewisville, Texas. It is a provider of custom and catalog peptides, custom oligos, antibodies, organic synthesis, and analytical services. Biomedical researchers worldwide in universities, biotech companies, private clinics, and government agencies use products from Bio-Synthesis, Inc. in studies ranging from PCR diagnostics to cancer research and the Human Genome Project.
RGD was identified as the minimal recognition sequence within fibronectin required for cell attachment by Ruoslahti and Pierschbacher in the early 1980s. To do this, the authors synthesized various peptides based on the hypothesized cell attachment site of fibronectin. They then coupled those peptides to protein-coated plastic and tested each for cell attachment-promoting activity. Only those that contained the RGD sequence were found to enhance cell attachment. Further, they showed that peptides containing RGD were able to inhibit cell attachment to fibronectin-coated substrates, whereas peptides not containing RGD did not. These foundational studies also identified the cellular receptors that recognize the sequence. These studies utilized a synthetic RGD-containing peptide to isolate the putative receptors, and then demonstrated that liposomes containing the isolated proteins could bind to fibronectin, in much the same way as cells with surface receptors. The discovered receptors were later named integrins. The RGD motif is presented in slightly different ways in different proteins, making it possible for the many RGD-binding integrins to selectively distinguish individual adhesion proteins.
Sources: en.wikipedia.org
Common solvents include sterile water, phosphate-buffered saline, and water-acetonitrile mixtures. The choice depends on the peptide's solubility profile and the buffer compatibility for the intended application. Manufacturers often provide a recommended solvent on the product information sheet.
Solutions are typically stored at -80°C in single-use aliquots to avoid repeated freeze-thaw cycles. They should be protected from light and kept in low-binding containers. Some peptides require a carrier protein or cryoprotectant to prevent adsorption and aggregation.
Records should include the lot number, date received, storage temperature, and any handling steps. A log of freeze-thaw cycles and aliquot preparation helps track stability. This documentation supports traceability and quality control.
Lyophilized peptides have low water activity, which slows hydrolysis and many oxidative pathways. Low temperatures further reduce residual chemical reactivity and microbial growth risk. The exact temperature depends on peptide stability data and expected storage duration.